EULAV Asset Management

SEC CIK: 0001540826
Latest filing: Jul 29, 2026

SEC filings (opens in a new tab)

VRTX holding history

Vertex Pharmaceuticals Inc in every 13F filed by EULAV Asset Management, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

VRTX overview All 13F holders of VRTX Full Q2 2026 holdings

Shares (Q2 2026): 19,500
Value: $9.69M
% of portfolio: 0.3%
Quarters held: 22; Since Q1 2021

Holdings of VRTX by EULAV Asset Management, by quarter
Quarter	Shares	Value	% of portfolio	Share change	Action	All holders
Q2 2026	19,500	$9.69M	0.3%	−1,500−7.1%	Reduced	Holders
Q1 2026	21,000	$9.38M	0.3%	−1,000−4.5%	Reduced	Holders
Q4 2025	22,000	$9.97M	0.3%	00.0%	Unchanged	Holders
Q3 2025	22,000	$8.62M	0.2%	−700−3.1%	Reduced	Holders
Q2 2025	22,700	$10.1M	0.2%	−5,800−20.4%	Reduced	Holders
Q1 2025	28,500	$13.8M	0.3%	00.0%	Unchanged	Holders
Q4 2024	28,500	$11.5M	0.3%	−3,000−9.5%	Reduced	Holders
Q3 2024	31,500	$14.7M	0.4%	−4,500−12.5%	Reduced	Holders
Q2 2024	36,000	$16.9M	0.5%	−1,900−5.0%	Reduced	Holders
Q1 2024	37,900	$15.8M	0.4%	−500−1.3%	Reduced	Holders
Q4 2023	38,400	$15.6M	0.5%	+5,000+15.0%	Added	Holders
Q3 2023	33,400	$11.6M	0.4%	−2,100−5.9%	Reduced	Holders
Q2 2023	35,500	$12.5M	0.5%	−2,000−5.3%	Reduced	Holders
Q1 2023	37,500	$11.8M	0.5%	−4,500−10.7%	Reduced	Holders
Q4 2022	42,000	$12.1M	0.5%	−6,010−12.5%	Reduced	Holders
Q3 2022	48,010	$13.9M	0.6%	−5,998−11.1%	Reduced	Holders
Q2 2022	54,008	$15.2M	0.6%	−5,999−10.0%	Reduced	Holders
Q1 2022	60,007	$15.7M	0.5%	−19,993−25.0%	Reduced	Holders
Q4 2021	80,000	$17.6M	0.4%	−28,000−25.9%	Reduced	Holders
Q3 2021	108,000	$19.6M	0.5%	−34,000−23.9%	Reduced	Holders
Q2 2021	142,000	$28.6M	0.8%	−8,000−5.3%	Reduced	Holders
Q1 2021	150,000	$32.2M	0.9%	–	–	Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.